Pharmaceutical Contract Development And Manufacturing Market Size, Share, Growth Opportunities, Trends Analysis & Global Industry Forecast Report, 2023-2030
GMI Research analysis indicates that the Pharmaceutical Contract Development and Manufacturing Market size was estimated at USD 163.6 billion in 2022 and is slated to register a single digit CAGR of 7.6% over the forecast period, and is projected to reach USD 294.0 billion in 2030
Pharmaceutical Contract Development and Manufacturing Market Overview
A contract manufacturing organization also called contract development and organization, is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing.
To have an edge over the competition by knowing the market dynamics and current trends of “Pharmaceutical Contract Development and Manufacturing Market”, request for Sample Report here
Major Pharmaceutical Contract Development and Manufacturing Market Drivers
Increasing investment and expenditure on pharmaceutical research and development activities by leading companies to encourage drug development and product innovation stands to be a major factor fuelling the Pharmaceutical Contract Development and Manufacturing Market. As per the Congressional Budget Office, in 2019, approximately $ 83 billion were allocated for the pharmaceutical R&D expenditure in the United States. Additionally, the development in cell and gene therapies along with the increasing emphasis on specialty medicines are forecast to expand the market growth. Emerging need for advanced processes and production technologies have bolstered the demand for CMOs in the pharmaceutical industry. The growing pressure on healthcare vendors to reduce healthcare costs and surging demand for generic medicine to enhance the therapeutic efficiency will augment the demand for CMOS.
Moreover, as per the Pharmaceutical Contract Development and Manufacturing Market forecast, increasing investment by leading market participants in infrastructure, personnel, and technology to earn a competitiveness in the market and the emphasis of end-to-end business vendors service o providing value-added services for a risk-sharing business model will bolster growth in this industry. Growing dependence on contract manufacturing due to the increasing complications in biopharmaceuticals and the highly personalized medical therapies have stimulated the expansion of CMO market.
Restraint in the Pharmaceutical Contract Development and Manufacturing Market
However, stringent government regulations in the manufacturing of API and drugs is the major factor which is likely to hamper the growth of the market.
Do you want to know more about the Research process and detailed Methodology, Request Research Methodology of this report
Service – Segment Analysis
Based on the service, pharmaceutical manufacturing services is witnessed to grow at a higher CAGR in the market over the forecast period. This is due to the high demand and consumption of generic drugs and liquid dosage forms, which has led to the expansion of the market. In addition, it also offers the advantages like, it is cost effective, advanced skills, quality assurance, which has led to the better efficiency and expansion of the sector.
End-User – Segment Analysis
Based on the end-user, big pharmaceutical companies are witnessed to grow at a higher CAGR in the market over the forecast period. This is due to the rising number of mergers and acquisitions in the pharmaceutical sector, which has helped in changing the landscape of the market. For instance, acquisitions by the key players in the market for example, in 2019 Catalent acquired Paragon Bio services, in 2017 Thermofisher Scientific acquitted Patheon’s, etc. which has driven the market.
In case, any of your pain points areas are not covered in the current scope of this report, Request for Free Customization here
Regional – Segment Analysis:
Based on the regional coverage Asia-Pacific is expected to grow at a higher CAGR in the market over the forecast period. This is due to the strategic initiatives by the countries like India, China, and Japan, which have helped in the regional expansion of the market. For instance, “Ministry of Health and Family Welfare India”, has announced US$ 9.30 billion under the 2020-2021 budget which has shifted the paddles for the market in the Asia-Pacific.
Top Market Players
Various notable players operating in the market, include, Boehringer Ingelheim GmbH, Lonza, Grifols S.A, Jubilant Life Sciences Limited, Pfizer, Inc. (Pfizer CenterOne), Charles River Laboratories International, Inc., Albany Molecular Research, Inc., Covance, Inc. (LabCorp), QuintilesIMS, Baxter BioPharma Solutions, among others.
Key Developments:
-
- In 2021, Samsung BioLogics (South Korea) entered into a Development and Manufacturing Agreement with Kineta (US) for Anti-VISTA Antibody Immunotherapy
- In 2021, Lonza Group (Switzerland) entered into an agreement with Aruvant Science (US) to carry out process development (one-time investigational gene therapy—ARU-1801) for sickle-cell treatment in the US
- In 2021, Lonza entered into an agreement with Aruvant Science, for sickle-cell treatment in the US, leading to the expansion of both the companies.
- In 2020, Catalent (US) acquired Skeletal Theray Support (Belgium). Under this acquisition, Catalent manufactured clinical material for Bone Therapeutics’ drug, ALLOB, an allogeneic osteoblastic cell therapy product
Segments covered in the Report:
The global Pharmaceutical Contract Development and Manufacturing market has been segmented on the basis of service, end-user, and regions. Based on service, the market is segmented into pharmaceutical manufacturing sevices, drug development services and biologics manufacturing devices. Based on end-user, the market is segmented into big pharmaceutical companies, small & medium sized pharmaceutical companies, generic pharmaceutical companies, and others.
For detailed scope of the “Pharmaceutical Contract Development and Manufacturing Market” report request a Sample Copy of the report
|
Report Coverage |
Details |
| Market Revenues (2022) |
USD 163.6 billion |
| Market Base Year |
2022 |
| Market Forecast Period |
2023-2030 |
| Base Year & Forecast Units |
Revenues (USD billion) |
| Market Segment | By Service, By End-User, By Region |
| Regional Coverage | Asia Pacific, Europe, North America, and RoW |
| Companies Profiled | Boehringer Ingelheim GmbH, Lonza, Grifols S.A, Jubilant Life Sciences Limited, Pfizer, Inc. (Pfizer CenterOne), Charles River Laboratories International, Inc., Albany Molecular Research, Inc., Covance, Inc. (LabCorp), QuintilesIMS, Baxter BioPharma Solutions, among others; a total of 10 companies covered. |
| 25% Free Customization Available | We will customize this report up to 25% as a free customization to address our client’s specific requirements |
Market Segmentation
Global Pharmaceutical Contract Development and Manufacturing Market by Service
-
- Pharmaceutical Manufacturing Devices
- Drug Development Services
- Biologics Manufacturing Devices
Global Pharmaceutical Contract Development and Manufacturing Market by End-User
-
- Big Pharmaceutical Companies
- Small & Medium Sized Pharmaceutical Companies
- Generic Pharmaceutical Companies
- Others
Global Pharmaceutical Contract Development and Manufacturing Market by Region
-
-
North America Pharmaceutical Contract Development and Manufacturing Market (Option 1: As a part of the free 25% customization)
- By Service
- By End-User
- US Market All-Up
- Canada Market All-Up
-
Europe Pharmaceutical Contract Development and Manufacturing Market (Option 2: As a part of the free 25% customization)
- By Service
- By End-User
- UK Market All-Up
- Germany Market All-Up
- France Market All-Up
- Spain Market All-Up
- Rest of Europe Market All-Up
-
Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market (Option 3: As a part of the free 25% customization)
- By Service
- By End-User
- China Market All-Up
- India Market All-Up
- Japan Market All-Up
- Rest of APAC Market All-Up
-
RoW Pharmaceutical Contract Development and Manufacturing Market (Option 4: As a part of the free 25% customization)
- By Service
- By End-User
- Brazil Market All-Up
- South Africa Market All-Up
- Saudi Arabia Market All-Up
- UAE Market All-Up
- Rest of world (remaining countries of the LAMEA region) Market All-Up
-
Major Players Operating in the Pharmaceutical Contract Development and Manufacturing (Option 5: As a part of the Free 25% Customization – Profiles of 5 Additional Companies of your Choice)
-
- Boehringer Ingelheim GmbH
- Lonza
- Grifols S.A
- Jubilant Life Sciences Limited
- Pfizer, Inc. (Pfizer CenterOne)
- Charles River Laboratories International, Inc.
- Albany Molecular Research, Inc.
- Covance, Inc. (LabCorp)
- QuintilesIMS
- Baxter BioPharma Solutions
Why GMI Research
